Cancer Immunotherapy

HDAC6-IN-73 is a highly potent and selective HDAC6 inhibitor with an IC₅₀ of 0.007 μM ± 0.001, ~1771-fold selectivity over HDAC1, ~131-fold selectivity over HDAC8, and antiproliferative activity in hematological cancer cell lines.HDAC6-IN-73 can be used for the research of hematological malignancies.

TLR7 agonist 17 (compound 20) is a potent TLR7 agonist with EC₅₀ values of 12 nM and 17 nM for hTLR7 and mTLR7, respectively. TLR7 agonist 17 shows anticancer activity.

PROTAC NAMPT Degrader-31 is a PROTAC degrader that targets and degrades NAMPT by recruiting cereblon. It exhibits DC₅₀ values of 9.31 nM and 12.54 nM against NAMPT in MDA-MB-231 and 4T1 cells, respectively, and an IC₅₀ value of 15.05 nM for NAMPT enzymatic activity. PROTAC NAMPT Degrader-31 induces NAMPT degradation via the ubiquitin-proteasome system, inhibits NAMPT enzymatic activity, and reduces NAD⁺ levels through the NAD⁺ salvage pathway. It can be used in research related to triple-negative breast cancer.

2-Thiouracil-¹³C,¹⁵N₂ is the ¹³C, ¹⁵N labeled 2-Thiouracil. 2-Thiouracil (Thiouracil) is an antithyroid compound. 2-Thiouracil can function as a highly specific melanoma seeker. 2-Thiouracil is a selective inhibitor of neuronal nitric oxide synthase (nNOS) with a Ki of 20 μM.

Crotalicidin is an antimicrobial peptide and anti-tumor peptide that can effectively inhibit the activity of Gram-negative bacteria and tumor cells. Crotalicidin can be obtained from rattlesnake venom. Crotalicidin can be used in the study of microbial infections and cancer.

MIF-IN-5 (compound 1d) is a potent and reversible macrophage migration inhibitory factor (MIF) competitive inhibitor with an IC₅₀ of 4.8 μM and a K_i value of 3.3 μM, respectively.

ML210-ansaFc (Compound III-13) is a covalent GPX4 inhibitor with a -ferrocenophane group (IC₅₀ of 3.4 μM). ML210-ansaFc potently induces ferroptosis by increasing the level of ROSand promoting lipid peroxidation (LPO) in cancers cells. ML210-ansaFc has an anticancer activity and suppresses tumor growth in tumor 3D spheroids. ML210-ansaFc can be used for cancer therapy resistance research.

Emodic acid (NSC624610) is an anthraquinone compound isolated from A. microcarpus, which can inhibit the proliferation of cancer cells by inhibiting the activity of NF-κB. Emodic acid can also inhibit the phosphorylation of p38, ERK and JNK, the secretion of tumor-promoting cytokines IL-1β and IL-6, and the expression of VEGF and MMP, thereby inhibiting the invasion and migration potential of cancer cells.

ABX-MA1 is a humanized IgG2 monoclonal antibody inhibitor targeting MCAM/MUC18. ABX-MA1 significantly decreases homotypic aggregation and heterotypic adhesion to HUVECs, and the formation of experimental lung metastasis. ABX-MA1 potently inhibits tumor growth, angiogenesis, and MMP-2 expression in A375SM/WM2664 xenograft mice model, promising for melanoma research.

Cochinchinone P is a retinoid X receptor-α (RXRα) inhibitor that inhibits 9-cis-retinoic acid (HY-15128)-induced transcriptional activity of RXRα in vitro. Cochinchinone P can be used in cancer research.

ABHD antagonist 1 possesses ABHD6 (α/β-Hydrolase domain containing 6) inhibitory activity, involving the regulation of biochemical pathways involved in ABHD6, thereby affecting cell function and inflammatory response. ABHD antagonist 1 can be used in pain, neuropathic diseases, inflammatory diseases. Autoimmune diseases, metabolic diseases, and cancer research.

GNUV201 is a PD-1 inhibitor with cross-reactivity in humans, mice and monkeys, which effectively blocks the PD-1/PD-L1 interaction. GNUV201 activates T cells and restores their anti-tumor activity, effectively inducing tumor regression. GNUV201 can be used in the research of related diseases such as colorectal cancer, melanoma, pancreatic cancer and colon cancer.

CTCE-9908 TFA is a potent and selective CXCR4 antagonist. CTCE-9908 TFA induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells.

PC-046 is a multi-target inhibitor for tyrosine receptor kinase B (TrkB), IRAK-4 and Pim-1, with IC₅₀ of 13.4 μM, 15.4 μM and 19.1 μM, respectively. PC-046 exhibits cytotoxicity against pancreatic cancer cell BxPC3 with IC₅₀ of 7.5-130 nM. PC-046 induces apoptosis and arrests cell cycle at G2/M phase in BxPC3. PC-046 exhibits antitumor efficacy and exhibits good pharmacokinetic characteristics in mice.

Antibacterial agent 189 (compound 3a) is a potent antimicrobial agent. Antibacterial agent 189 offers high binding energy against the target OMPA/exo-1,3-beta-glucanase proteins. Antibacterial agent 189 exhibits the potent antimicrobial activities against E. coli, P. aeruginosa, S. aureus, B. subtilis, C. Albicans and A. flavus. Antibacterial agent 189 shows high binding energy against target SMO and SUFU/GLI-1 proteins.

Deferasirox (Standard) is the analytical standard of Deferasirox. This product is intended for research and analytical applications. Deferasirox (ICL 670) is an orally available iron chelator used for the management of transfusional iron overload.

PROTAC AURKA degrader-4 is a AURKA PROTAC degrader with a DC₅₀ of 25.62 nM (Jurkat cells). PROTAC AURKA degrader-4 recruits the CRBN E3 ubiquitin ligase via the ubiquitin-proteasome system. PROTAC AURKA degrader-4 disrupts both the catalytic and non-catalytic functions of AURKA, including its interactions with TPX2 and c-Myc. PROTAC AURKA degrader-4 induces G2/M phase arrest and apoptosis. PROTAC AURKA degrader-4 exhibits enhanced antiproliferative activity and in vivo antitumor efficacy in models with high CRBN and AURKA expression. PROTAC AURKA degrader-4 can be used for the research of acute lymphoblastic leukemia.

Trimethoprim sulfate is a bacteriostatic antibiotic and an orally active dihydrofolate reductase inhibitor. Trimethoprim sulfate is active against a wide range of Gram-positive and Gram-negative aerobic bacteria. Trimethoprim sulfate has the potential for the research of urinary tract infections, Shigellosis and Pneumocystis pneumonia. Trimethoprim sulfate can inhibit infection of Influenza A virus in chick embryo when combinated with zinc.

PRLX-93936 analog 1 is a TRIM21-targeting cytotoxin. PRLX-93936 analog 1 binds to the TRIM21 PRYSPRY domain, inducing TRIM21-mediated ubiquitination and degradation of nucleoporin proteins. PRLX-93936 analog 1 impairs nuclear trafficking, triggering cell death. PRLX-93936 analog 1 exhibits TRIM21-dependent cytotoxicity, suppressible by TRIM21 ligand HGC1g. PRLX-93936 analog 1 can be used for the research of acute myeloid leukemia.

NF023 is a compound that inhibits X-BIR1/TAB1 assembly activity. NF023 can affect cell survival signaling pathways by interfering with XIAP-mediated NF-κB activation. NF023 also shows potential as a selective P2X1 adenylate receptor antagonist. This compound has the potential to synergize with existing pro-apoptotic drugs and play an important role in cancer suppression.